SCHEMBL4535745

SCHEMBL4535745

Cc1cc(Nc2nc(N3CC4(CCN(C(=O)OC(C)(C)C)CC4)C3)nc3ncccc23)[nH]n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 5/20 0.41
▸ PARP1 P09874 5/20 0.40
▸ CYP11B2 P19099 1/20 0.40
▸ TNKS O95271 3/20 0.39
▸ TNKS2 Q9H2K2 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ KIT P10721 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ MMP2 P08253 1/20 0.37
▸ MMP13 P45452 1/20 0.37
▸ NAMPT P43490 1/20 0.37
▸ ACHE P22303 1/20 0.36
▸ GPR119 Q8TDV5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4512984 0.87 HSD17B10 (0.49) ALDH1A1CYP3A4HSD17B10CYP2D6USP2
SCHEMBL4527109 0.85 POLB (0.38) KITPOLBACHEGPR119
SCHEMBL4511804 0.82 ALDH1A1 (0.44) ALDH1A1CYP3A4HSD17B10CYP2D6USP2
SCHEMBL4524778 0.79 JAK2 (0.34) —
SCHEMBL5263624 0.73 CCR4 (0.34) —
SCHEMBL4512965 0.71 AXL (0.35) ACHE
SCHEMBL4531067 0.71 PAK4 (0.37) —
SCHEMBL4512389 0.71 AXL (0.36) ALDH1A1HSD17B10HPGD
SCHEMBL30456119 0.71 KIT (0.49) PARP1CYP11B2ALDH1A1CYP3A4HSD17B10
SCHEMBL4511771 0.69 KMT5A (0.45) ALDH1A1HSD17B10CYP2D6HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831216-A2 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2007-09-12 — — EP claimed
WO-2006067614-A2 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2006-06-29 — — WO claimed
US-20090281073-A1 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS BHATTACHARYA SAMIT KUMAR 2009-11-12 — — US disclosed
EP-1831216-A2 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2007-09-12 — — EP disclosed
WO-2006067614-A2 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2006-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281073-A1 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS CCNY, TP53, CCNE1 ACACB 3019/4885PARP1 366/4885CYP11B2 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback